T1	Participants 48 73	symptomatic endometriosis
T2	Participants 143 165	endometriosis patients
T3	Participants 678 798	201 patients enrolled in the initial trial, 123 completed at least 280 days of therapy and entered the follow-up period.
T4	Participants 1571 1605	symptomatic endometriosis patients
